Montelukast Zentiva (Montelukast Sodium)

Montelukast Zentiva, a leukotriene receptor antagonist, is used to manage conditions driven by cysteinyl leukotriene activity, providing anti‑inflammatory and bronchodilatory benefits.

• Asthma: provides maintenance therapy that reduces airway inflammation, improves symptom control, and lowers the risk of asthma attacks in both adults and children.
• Allergic rhinitis: relieves nasal congestion, rhinorrhea, sneezing, and itchy or watery eyes caused by seasonal or perennial allergens.
• Exercise‑induced bronchoconstriction: taken prior to activity to prevent the acute narrowing of airways that can limit performance and cause respiratory distress.

• Montelukast selectively blocks the cysteinyl leukotriene receptor type 1 (CysLT1) on airway smooth‑muscle cells, glands and inflammatory cells. By antagonizing the binding of leukotriene D4 and related mediators, it prevents leukotriene‑induced bronchoconstriction, mucus secretion and vascular permeability, thereby reducing airway inflammation and hyper‑responsiveness. The inhibition is competitive and reversible, leading to sustained reduction of leukotriene‑mediated effects throughout the dosing interval. This pharmacologic action supports long‑term control of asthma and allergic symptoms.

Montelukast may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate headache reported in clinical use.
• Abdominal pain: occasional stomach discomfort or cramps.
• Cough: transient dry cough without infection.
• Nausea: feeling of queasiness, often resolves without treatment.
• Diarrhea: loose stools that are usually self‑limiting.

Serious or Rare Side Effects

• Allergic reactions: rash, angioedema, or anaphylaxis requiring immediate medical attention.
• Neuropsychiatric events: mood changes, agitation, depression, or suicidal thoughts.
• Hepatic enzyme elevation: rare increase in liver function tests indicating possible liver involvement.
• Stevens‑Johnson syndrome: rare severe skin reaction.

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use.

• Pregnancy: safety not established; use only if potential benefit justifies the risk.
• Breastfeeding: limited data; monitor infant for possible adverse effects.
• Hepatic impairment: reduced metabolism may require careful monitoring of efficacy and tolerability.
• Concomitant phenobarbital or other enzyme inducers: may lower drug levels and diminish therapeutic effect.
• Asthma control: do not discontinue abruptly; assess for worsening symptoms.
• Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Montelukast can interact with other medicines, altering its effectiveness or increasing the risk of adverse events.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): may markedly reduce plasma concentrations and compromise efficacy.
• Ritonavir: may increase Montelukast levels, potentially enhancing side‑effects.

Moderate Interactions (Monitor Closely)

• Fluconazole: moderate CYP3A4 inhibition may raise Montelukast exposure.
• Warfarin: monitor INR as Montelukast may affect anticoagulant control.
• Beta‑agonists: no direct pharmacokinetic interaction, but combined use requires assessment of overall asthma control.